DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
This grant funds research aimed at developing therapeutic interventions for Amyotrophic Lateral Sclerosis (ALS).
About this program
The DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award supports innovative research projects focused on the development of therapies for ALS. This program is designed to encourage researchers to explore new avenues in ALS treatment, ultimately aiming to improve patient outcomes. The grant is open to a variety of research entities, including academic institutions, nonprofit organizations, and private sector companies engaged in ALS research. Eligible applicants will be expected to demonstrate a clear plan for therapeutic development, including preclinical and clinical trial phases. The program seeks to foster collaboration among researchers, clinicians, and industry partners to accelerate the translation of scientific discoveries into effective therapies for ALS patients. Successful proposals will address critical gaps in current ALS treatment options and provide a roadmap for future research efforts.
Eligibility
Academic institutions, nonprofit organizations, and private sector companies engaged in ALS research.